What is KPV?
KPV is the three C-terminal residues of alpha-melanocyte-stimulating hormone — lysine, proline, valine — which is itself cut from the pro-opiomelanocortin precursor (UniProt P01189).
How does KPV work, according to the published research?
The sources recorded here describe the tripeptide entering cells through the PepT1 di/tripeptide transporter and, in human cell lines, acting inside the cell on NF-κB signalling — one of them locating the interaction at the importin-α3 binding site on p65RelA. A keratinocyte study found no rise in cyclic AMP with this tripeptide, and one mouse study reports its effect persisting in animals whose melanocortin-1 receptor is non-functional. No source here establishes a receptor the tripeptide binds.
- In immortalised human bronchial epithelial cells (16HBE14o-) stimulated with TNFα or respiratory syncytial virus, KPV produced a concentration-dependent inhibition of NF-κB reporter activity, matrix metalloproteinase-9 activity and IL-8 and eotaxin secretion. The KPV effect was associated with the peptide's own nuclear import, stabilisation of IκBα and suppressed nuclear translocation of YFP-tagged p65RelA, and competition assays indicated an interaction between KPV and the importin-α3 binding site on p65RelA. (Land, 2012, PMID 22837805)
- No elevation of cyclic AMP was detected in HaCaT cells or in normal human keratinocytes in response to α-MSH, KPV or ACTH peptides, although the anti-inflammatory action of α-MSH had been assumed to be cyclic-AMP dependent. (Elliott et al., 2004, PMID 15102092)
- Reports that α-MSH (1-13) and its C-terminal tripeptide KPV, tested together as 'α-MSH peptides', significantly inhibited Staphylococcus aureus colony formation and reduced the viability and germ-tube formation of Candida albicans, over a broad concentration range including the picomolar. Cellular cAMP was significantly higher in the yeast after exposure and the adenylyl cyclase inhibitor dideoxyadenosine partly reversed the killing, which the authors read as cAMP involvement. The peptides did not lower killing of either organism by human neutrophils. (Cutuli et al., 2000, PMID 10670585)
What has published research on KPV found, and what are its limits?
This page records 6 publications, reporting laboratory (in vitro) work in 5, animal work in 2. Each is listed with its identifier under References.
No human study is represented on this page.
Evidence represented on this page: in vitro and animal.
No human research is represented.
The page reviews 6 published studies, and each figure is reported for the study that published it; results are not pooled across studies.
2 of these publications carry a note on whether they studied this exact material.
Every figure on this page comes from a cell-culture or animal study, using material prepared for that study. It is not the research material PepGenex supplies and no result here transfers to it, or to people.
Is KPV approved by the U.S. FDA?
This page cites no FDA approval record for KPV; PepGenex Science states a U.S. regulatory status only where a sourced record exists.
PepGenex research materials are not FDA approved and are not for human or veterinary use.